202 related articles for article (PubMed ID: 27928647)
1. Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy.
Kumar P; Lakshmi YS; Kondapi AK
Pharm Res; 2017 Feb; 34(2):257-268. PubMed ID: 27928647
[TBL] [Abstract][Full Text] [Related]
2. An oral formulation of efavirenz-loaded lactoferrin nanoparticles with improved biodistribution and pharmacokinetic profile.
Kumar P; Lakshmi YS; Kondapi AK
HIV Med; 2017 Aug; 18(7):452-462. PubMed ID: 28000390
[TBL] [Abstract][Full Text] [Related]
3. Improved Safety, Bioavailability and Pharmacokinetics of Zidovudine through Lactoferrin Nanoparticles during Oral Administration in Rats.
Kumar P; Lakshmi YS; C B; Golla K; Kondapi AK
PLoS One; 2015; 10(10):e0140399. PubMed ID: 26461917
[TBL] [Abstract][Full Text] [Related]
4. Triple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticles.
Lakshmi YS; Kumar P; Kishore G; Bhaskar C; Kondapi AK
Sci Rep; 2016 May; 6():25479. PubMed ID: 27151598
[TBL] [Abstract][Full Text] [Related]
5. Comparative studies of lamivudine-zidovudine nanoparticles for the selective uptake by macrophages.
Sankar V; Nareshkumar PN; Ajitkumar GN; Penmetsa SD; Hariharan S
Curr Drug Deliv; 2012 Sep; 9(5):506-14. PubMed ID: 22452408
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
[TBL] [Abstract][Full Text] [Related]
8. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
Kuritzkes DR; Ribaudo HJ; Squires KE; Koletar SL; Santana J; Riddler SA; Reichman R; Shikuma C; Meyer WA; Klingman KL; Gulick RM;
J Infect Dis; 2007 Apr; 195(8):1169-76. PubMed ID: 17357053
[TBL] [Abstract][Full Text] [Related]
9. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Antiproliferative Activity, Safety and Biodistribution of Oxaliplatin and 5-Fluorouracil Loaded Lactoferrin Nanoparticles for the Management of Colon Adenocarcinoma: an In Vitro and an In Vivo Study.
Ahmed F; Kumari S; Kondapi AK
Pharm Res; 2018 Jul; 35(9):178. PubMed ID: 30014319
[TBL] [Abstract][Full Text] [Related]
12. [Adherence, pharmacokinetic "tolerance capacity" and HIV resistance development].
Mossdorf E; Hirsch HH
Praxis (Bern 1994); 2006 Aug; 95(33):1237-9. PubMed ID: 16939126
[No Abstract] [Full Text] [Related]
13. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
[TBL] [Abstract][Full Text] [Related]
14. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Cooper DA; Heera J; Goodrich J; Tawadrous M; Saag M; Dejesus E; Clumeck N; Walmsley S; Ting N; Coakley E; Reeves JD; Reyes-Teran G; Westby M; Van Der Ryst E; Ive P; Mohapi L; Mingrone H; Horban A; Hackman F; Sullivan J; Mayer H
J Infect Dis; 2010 Mar; 201(6):803-13. PubMed ID: 20151839
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
16. Design of Lamivudine Loaded Nanoparticles for Oral Application by Nano Spray Drying Method: A New Approach to use an Antiretroviral Drug for Lung Cancer Treatment.
Öztürk AA; Namlı İ; Güleç K; Görgülü Ş
Comb Chem High Throughput Screen; 2020; 23(10):1064-1079. PubMed ID: 32209039
[TBL] [Abstract][Full Text] [Related]
17. A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery.
Ye Y; Sun Y; Zhao H; Lan M; Gao F; Song C; Lou K; Li H; Wang W
Int J Pharm; 2013 Dec; 458(1):110-7. PubMed ID: 24126038
[TBL] [Abstract][Full Text] [Related]
18. Glycyrrhizin conjugated chitosan nanoparticles for hepatocyte-targeted delivery of lamivudine.
Mishra D; Jain N; Rajoriya V; Jain AK
J Pharm Pharmacol; 2014 Aug; 66(8):1082-93. PubMed ID: 24641311
[TBL] [Abstract][Full Text] [Related]
19. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
Lamorde M; Schapiro JM; Burger D; Back DJ
AIDS; 2014 Nov; 28(17):2551-63. PubMed ID: 25574958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
